Abstract
BackgroundInterleukin-10 (IL-10) is a powerful modulator of anti-tumor immune responses. The IL-10 promoter region polymorphisms are known to regulate IL-10 production, and thus are thought to be implicated in tumorigenesis. Recently, the roles of these polymorphisms in urologic cancer have been extensively studied, with conflicting results. Therefore, we conducted the present meta-analysis to better elucidate the correlations between IL-10 polymorphisms and urologic cancer risk.MethodsEligible articles were searched in PubMed, Medline, Embase, Scopus and CNKI up to May 2016. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to detect any potential associations between IL-10 polymorphisms and the risk of urologic cancer.ResultsA total of 22 case–control studies including 8572 patients and 9843 controls were analyzed. The overall meta-analysis results showed that IL-10 −592C>A polymorphism was significantly associated with urologic cancer in CA versus AA (P = 0.04, OR 0.87, 95% CI 0.76–0.99) and AA versus CC+CA (P = 0.03, OR 1.15, 95% CI 1.02–1.31). Subgroup analyses by cancer types suggested there were significant associations between all the three investigated IL-10 polymorphisms and bladder cancer. However, subgroup analyses by ethnicity only detected a weak association between IL-10 −819C>T and Asian population.ConclusionsOur findings suggests that IL-10 −592C>A polymorphism may implicate with urologic cancer risk. Besides, promoter region polymorphisms of IL-10 may serve as potential biological markers, especially for bladder cancer. Furthermore, IL-10 −819C>T polymorphism may contribute to urologic cancer susceptibility in Asians while all the three studied variants of IL-10 did not relate to Caucasian urologic cancer predisposition.
Highlights
Interleukin-10 (IL-10) is a powerful modulator of anti-tumor immune responses
When data were stratified by cancer types, we found that IL-10 −592C>A polymorphism was significantly associated with bladder cancer risk in CC versus AA (P = 0.002, Odds ratios (ORs) 0.51, 95% confidence intervals (CIs) 0.33–0.78), CA versus AA (P = 0.004, OR 0.64, 95% CI 0.48–0.87), CC versus CA+AA (P = 0.02, OR 0.62, 95% CI 0.41–0.93), CA versus CC+AA (P = 0.04, OR 0.74, 95% CI 0.56–0.99), AA versus CC+CA (P = 0.0004, OR 1.65, 95% CI 1.25– 2.19), and C versus A (P = 0.00001, OR 0.66, 95% CI 0.54–0.82)
In conclusion, the current meta-analysis suggests that IL10 −592C>A polymorphism may implicate with urologic cancer risk
Summary
Interleukin-10 (IL-10) is a powerful modulator of anti-tumor immune responses. The IL-10 promoter region polymorphisms are known to regulate IL-10 production, and are thought to be implicated in tumorigenesis. Certain polymorphisms located in the promoter region of IL-10 gene (−592C>A, −819C>T and −1082A>G), which regulate the expression level of IL-10 protein (Turner et al 1997; Kingo et al 2005), were thought to be implicated in the pathogenesis of various kinds of cancers. Many genetic association studies have been carried out to investigate the potential correlations between IL-10 promoter region polymorphisms and urologic cancer risk. Results of these studies were controversial and the statistical power of individual studies was insufficient. We conducted the present meta-analysis to better assess the potential associations of IL-10 genetic polymorphisms with the risk of urologic cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
